Page 85 - MemoriaEHD-Eng

www.ciberehd.org

• M L, p--p s, C g, K g, F-C C, C-L-
Most relevant eNsaérezDeLuLgarrespooutsouDaKiserNáNDezarriLLootoLere
Na M. Imaging of hepatitis C virus infection in liver grafts after liver transplantation.J
scientific Hepatol. 2013 Aug;59(2):271-8.

articles
• Mariño z, Crespo g, D’aMato M, BraMBiLLa N, giaCoveLLi g, rovati L. Intravenous silibinin
monotherapy shows significant antiviral activity in HCV-infected patients in the peri-

transplantation period.J Hepatol. 2013 Mar;58(3):415-20.

• peDerseN J, CarLseN th, preNtoe J, raMirez s, JeNseN tB, ForNs x. Neutralization resistan-
ce of hepatitis C virus can be overcome by recombinant human monoclonal antibo-

dies.Hepatology. 2013 Nov;58(5):1587-97.

• Crespo g, CarrióN Ja, Coto-LLereNa M, Mariño z, LeNs s, pérez-DeL-puLgar s. Combina-
tions of simple baseline variables accurately predict sustained virological response in

patients with recurrent hepatitis C after liver transplantation.J Gastroenterol. 2013
Jun;48(6):762-9.

• s F, v r, B a, C Ja, F x, a Jg. Hemodynamic res-
ChepisuKotiCerzigottiarrióNorNsBraLDes
ponse to propranolol in patients with recurrent hepatitis C virus-related cirrhosis af-

ter liver transplantation: a case-control study.Liver Transpl. 2013 Apr;19(4):450-6.

TREATMENT OF CHRONIC HEPATITIS C: 1) Participation in clinical trials for the
Highlights
evaluation of the efficacy and safety of new antiviral molecules in immunocompe-
tent patients and 2) leadership, coordination and design of clinical studies using

new direct acting antivirals in special populations: decompensated cirrhotics, cirr-

hotics awaiting liver transplantation and liver transplant recipients.

DETECTION OF HCV ANTIGENS IN LIVER BIOPSIES: We have established an im-
munohistochemical assay to detect HCV antigens in formalin-fixed paraffin-em-

bedded liver tissue from HCV-infected liver transplant patients. The system has

been validated by assessing HCV antigens using confocal microscopy and we have
been able to confirm our results in samples provided by other transplant centers.

This method might be helpful for the diagnosis of severe hepatitis C recurrence
after liver transplantation in cases where the histopathological findings are not

conclusive.

HCV MASSIVE SEQUENCING: We have consolidated an active collaboration with

our CIBERehd partners at Institut de Recerca de l’Hospital Vall d’Hebron (Barce-
lona) to study HCV genetic evolution in the liver transplantation setting by ultra-

deep pyrosequencing (UDPS). In particular, we have performed a very detailed

analysis of HCV quasispecies dynamics and the competition of hepatitis C viral
strains in HCV-infected patients who underwent liver transplantation and received

a liver from an HCV-infected donor.

R & D COMPETITIVE PROJECTS: In January 2013 began the implementation of the
European project entitled “Human monoclonal antibody therapy to prevent hepa-
13
titis C virus reinfection of liver transplants: advancing lead monoclonal antibodies 20
T
into clinical trial” (Ref. 305500, HepaMAb). The main objectives of this project are: OR
1) the preclinical development of two monoclonal antibodies capable of blocking P
RE
HCV entry into hepatocytes and 2) the development of a proof of concept clinical L
A
trial for the prevention of graft infection after liver transplantation.
NU
N
A
D /
H
E
ER
IB
C

85